Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
hemic and lymphatic diseases | D006425 |
immune system diseases | D007154 |
Brand Name | Status | Last Update |
---|---|---|
aliqopa | New Drug Application | 2023-09-07 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
follicular lymphoma | — | D008224 | C82 |
Expiration | Code | ||
---|---|---|---|
COPANLISIB DIHYDROCHLORIDE, ALIQOPA, BAYER HEALTHCARE | |||
2024-09-14 | ODE-155 |
Code | Description |
---|---|
J9057 | Injection, copanlisib, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | — | C85.9 | 10 | 12 | 3 | — | 1 | 22 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 5 | 3 | 3 | — | 1 | 11 |
B-cell lymphoma | D016393 | — | — | 2 | 2 | 1 | — | — | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 2 | 3 | — | — | — | 4 |
Follicular lymphoma | D008224 | — | C82 | 1 | 2 | — | — | — | 3 |
Carcinoma | D002277 | — | C80.0 | 2 | 1 | — | — | — | 3 |
Leukemia | D007938 | — | C95 | 1 | 1 | — | — | — | 2 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | — | 2 | — | — | — | 2 |
Lymphoid leukemia | D007945 | — | C91 | — | 2 | — | — | — | 2 |
Mantle-cell lymphoma | D020522 | — | C83.1 | 1 | 2 | — | — | — | 2 |
T-cell lymphoma | D016399 | — | — | 2 | 1 | — | — | — | 2 |
Endometrial neoplasms | D016889 | EFO_0004230 | — | — | 2 | — | — | — | 2 |
Urinary bladder neoplasms | D001749 | — | C67 | 1 | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 6 | — | — | — | 1 | 7 |
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Non-small-cell lung carcinoma | D002289 | — | — | 2 | — | — | — | — | 2 |
Recurrence | D012008 | — | — | 1 | — | — | — | — | 1 |
Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | — | — | — | — | 1 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | — | — | — | — | 1 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
Invasive hydatidiform mole | D002820 | — | D39.2 | 1 | — | — | — | — | 1 |
Postmenopause | D017698 | — | — | 1 | — | — | — | — | 1 |
Medical sociology | D012962 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Copanlisib |
INN | copanlisib |
Description | Copanlisib, sold under the brand name Aliqopa, is a medication used for the treatment of adults experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies.
|
Classification | Small molecule |
Drug class | phosphatidylinositol 3-kinase (PI3K) inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21 |
PDB | — |
CAS-ID | 1032568-63-0 |
RxCUI | — |
ChEMBL ID | CHEMBL3218576 |
ChEBI ID | — |
PubChem CID | 24989044 |
DrugBank | DB12483 |
UNII ID | WI6V529FZ9 (ChemIDplus, GSRS) |